Evidence map›Paper›PMID 35495567›Full record

ArticleJVS-vascular science2022

Novel reinforcement of corrugated nanofiber tissue-engineered vascular graft to prevent aneurysm formation for arteriovenous shunts in an ovine model.

Hiroshi Matsushita, Hidenori Hayashi, Katherine Nurminsky, Tyler Dunn, Yusheng He, Isaree Pitaktong, Yojiro Koda, Shanxiu Xu, Vivian Nguyen, Takahiro Inoue and 4 more

Open access · goldAbstract read
In one paragraph

Article in JVS-vascular science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hiroshi MatsushitaSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Hidenori HayashiSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Katherine NurminskySection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Tyler DunnSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Yusheng HeSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Isaree PitaktongSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Yojiro KodaSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Shanxiu XuSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Vivian NguyenSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Takahiro InoueSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Daniel RodgersSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
Kevin NelsonNanofiber Solutions, LLC, Hilliard, OH.
Jed JohnsonNanofiber Solutions, LLC, Hilliard, OH.
Narutoshi HibinoSection of Cardiac Surgery, Biological Sciences Division, the University of Chicago, Chicago, IL.
University of Chicago · USNanofiber Solutions (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Many patients who require hemodialysis treatment will often require a prosthetic graft after multiple surgeries. However, the patency rate of grafts currently available commercially has not been satisfactory. Tissue engineering vascular grafts (TEVGs) are biodegradable scaffolds created to promote autologous cell proliferation and functional neotissue regeneration and, accordingly, have antithrombogenicity. Therefore, TEVGs can be an alternative prosthesis for small diameter grafts. However, owing to the limitations of the graft materials, most TEVGs are rigid and can easily kink when implanted in limited spaces, precluding future clinical application. Previously, we developed a novel corrugated nanofiber graft to prevent graft kinking. Reinforcement of these grafts to ensure their safety is required in a preclinical study. In the present study, three types of reinforcement were applied, and their effectiveness was examined using large animals. Methods: In the present study, three different reinforcements for the graft composed of corrugated poly-ε-caprolactone (PCL) blended with poly(L-lactide-co-ε-caprolactone) (PLCL) created with electrospinning were evaluated: 1) a polydioxanone suture, 2) a 2-0 polypropylene suture, 3) a polyethylene terephthalate/polyurethane (PET/PU) outer layer, and PCL/PLCL as the control. These different grafts were then implanted in a U-shape between the carotid artery and jugular vein in seven ovine models for a total of 14 grafts during a 3-month period. In evaluating the different reinforcements, the main factors considered were cell proliferation and a lack of graft dilation, which were evaluated using ultrasound examinations and histologic and mechanical analysis. Results: No kinking of the grafts occurred. Overall, re-endothelialization was observed in all the grafts at 3 months after surgery without graft rupture or calcification. The PCL/PLCL grafts and PCL/PLCL grafts with a polydioxanone suture showed high cell infiltration; however, they had become dilated 10 weeks after surgery. In contrast, the PCL/PLCL graft with the 2-0 suture and the PCL/PLCL graft covered with a PET/PU layer did not show any graft expansion. The PCL/PLCL graft covered with a PET/PU layer showed less cell infiltration than that of the PCL/PLCL graft. Conclusions: Reinforcement is required to create grafts that can withstand arterial pressure. Reinforcement with suture materials has the potential to maintain cell infiltration into the graft, which could improve the neotissue formation of the graft.

Indexed as

Arteriovenous shuntCorrugated nanofiber vascular graftLarge animal studySmaller diameter prosthetic graftsTissue-engineered vascular grafts

Identifiers

PMID35495567
PMCPMC9044007
OpenAlexW4285743199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.